Speaker: Jenna Frame, Ph.D.
Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Corp
Therapeutics targeting the immune system for oncology applications (such as immune checkpoint inhibitors, or ICIs) can in some cases lead to adverse effects in patients, and may affect multiple organ systems and/or cause CRS (cytokine release syndrome). Thus, predicting the safety and efficacy of novel therapeutics targeting the immune system in human subjects requires comprehensive profiling during preclinical study. Here, we provide an overview of the types of preclinical studies that can reveal immune-related adverse events in vivo and ex vivo, with a particular focus on efficacy and toxicity studies in humanized models. Case study data demonstrates that humanized models treated with ICIs can effectively mimic adverse effects seen in patients.
